The short answer
Copper is a redox-active metal that catalyses oxidation of thiols and thioethers, so co-lyophilising a copper complex with other peptides is a legitimate chemical question. BPC-157 has no cysteine or methionine. TB-500, supplied here as full-length thymosin beta-4, has no cysteine but one methionine, so that one residue is where the concern applies.
Key facts
- Copper source
- GHK-Cu complex, Cu(II)
- Copper property
- Redox-active, catalytic
- Would attack
- Cysteine thiols, methionine thioethers
- BPC-157 sequence
- GEPPPGKPADDAGLV (neither present)
- TB-500 (thymosin beta-4)
- No cysteine; one methionine
- Conclusion
- Limited to TB-500's one methionine
Why the question is worth asking
Copper catalyses oxidation, and the GLOW blend carries a copper complex. In protein chemistry this is well established: trace copper accelerates thiol oxidation, disulfide scrambling and methionine oxidation, which is why chelating agents appear in so many protein formulation buffers. Putting a copper complex in a vial with other peptides is therefore a fair thing to interrogate rather than assume away.
What copper would attack
Two residues specifically. Cysteine, whose free thiol is the most readily oxidised side chain in the standard set; copper-catalysed thiol oxidation is fast enough to be a formulation problem. And methionine, whose thioether oxidises to the sulfoxide, adding 16 Da and often reducing activity.
Research material referenced
GLOW 70mg, third-party HPLC tested
What is actually in the vial
In the GLOW 70mg vial, BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. No cysteine. No methionine. TB-500 here is full-length thymosin beta-4, 43 residues, with no cysteine but one methionine at position 6. So the thiol chemistry copper would catalyse has no substrate in the vial, and the thioether chemistry has exactly one.
Why this is a real finding rather than a reassurance
Because it would not have held for many other combinations. Glutathione is defined by a free thiol and oxidises to GSSG in air without any catalyst, so pairing it with a copper complex would be actively poor chemistry. IGF-1 LR3 carries three disulfide bonds whose correct pairing matters, and copper promotes disulfide scrambling. Neither belongs in a vial with GHK-Cu. This set avoids the thiol and disulfide problems entirely; what remains is one methionine.
What copper does not exempt the blend from
Ordinary hydrolysis, physical loss to surfaces, and the general instability of any peptide in solution. The copper question is narrow here; it is not the only question. GHK-Cu itself is also the component whose identity is most often misstated, with free GHK at 340.38 Da regularly quoted in place of the complex at 402.92.
How to check
A copper-catalysed oxidation product would show as a mass increase, most characteristically +16 Da on a methionine-containing peptide. In this blend that means the TB-500 component: a +16 Da species beside thymosin beta-4's 4,963 Da is the signature to look for, and the reason the vial is kept dry, cold and dark.
Frequently asked questions
Is it safe to blend a copper peptide with other peptides?
It depends entirely on the other peptides. Copper attacks cysteine thiols and methionine thioethers. BPC-157 contains neither; TB-500, as full-length thymosin beta-4, contains one methionine.
Which peptides should not be blended with copper?
Anything with a free thiol or disulfide bonds. Glutathione and IGF-1 LR3 are clear examples from this catalogue.
How would copper damage show up?
Most characteristically as a +16 Da oxidation satellite. Here it would appear on the TB-500 component, which carries the blend's one methionine.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedPickart L, GHK-Cu in prevention of oxidative stress. Oxid Med Cell Longev 2012 (PMID 22666519)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · GHK-Cu copper complex (CID 71587328)pubchem.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Thymosin beta-4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLOW (Blend) articles
- A Blend Fixes the Ratio and Keeps the ComplexityA co-lyophilised blend has a multi-agonist's fixed ratio without a single molecule's single pharmacokinetic profile. What that actually costs.
- One Volume, Three PeptidesThree peptides with different sizes and solubilities dissolve at different rates in one vial. What that means for technique and for patience.
- Storing a Blend: The Weakest Component GovernsThree peptides in one vial cannot be stored under three different conditions. The most demanding component sets the requirement for all of them.
- What Is GLOW? GHK-Cu, BPC-157 and TB-500A co-lyophilised blend of GHK-Cu, BPC-157 and TB-500 at 70mg total. What a three-component blend is, and the one figure it cannot give you.